Abstract Number: 1995 • 2015 ACR/ARHP Annual Meeting
Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?
Background/Purpose: Elderly-onset RA (EORA) patients (age of onset>60) are less likely to be treated with biologics even when accounting for disease activity compared to young-onset…Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…Abstract Number: 1998 • 2015 ACR/ARHP Annual Meeting
A National Electronic Health Record-Enabled Registry in Rheumatology: The ACR’s Rheumatology Informatics System for Effectiveness (RISE)
Title: A National Electronic Health Record-Enabled Registry in Rheumatology: The ACR's Rheumatology Informatics System for Effectiveness (RISE)Background/Purpose: In 2014, the ACR launched the Rheumatology Informatics…Abstract Number: 1999 • 2015 ACR/ARHP Annual Meeting
Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap
Background/Purpose: Increased mortality in RA is believed to be a consequence of inflammation. With improved treatment, mortality would be expected to decrease over time. The…Abstract Number: 2000 • 2015 ACR/ARHP Annual Meeting
Immune Response Against  β2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of arterial and venous thrombosis, and by recurrent abortions, in patients with persistent presence of autoantibodies…Abstract Number: 2001 • 2015 ACR/ARHP Annual Meeting
Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome
Background/Purpose: Human leukocyte antigen (HLA)-DRB1*07:01 is one of the susceptibility alleles for antiphospholipid syndrome (APS). Recently we have reported that beta-2-glycoprotein I (b2GPI) /HLA class…Abstract Number: 2002 • 2015 ACR/ARHP Annual Meeting
Dnase Treatment Protects Against DVT Formation in a Mouse Model of Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid antibodies, especially those targeting beta-2-glycoprotein I (β2GPI), have been shown to amplify thrombosis in mice. However, most published models have relied on endothelial…Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature
Background/Purpose: Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis. In systemic lupus erythematosus (SLE), there is a well-established…Abstract Number: 2004 • 2015 ACR/ARHP Annual Meeting
Procoagulant Property of a Novel Patient-Derived Autoimmune IgG Type Monoclonal Anticardiolipin Antibody That Binds to Beta 2 Glycoprotein Domain I but Not to Total Beta 2 Glycoprotein I Molecule
Background/Purpose: Anti-cardiolipin/β2 glycoprotein I (aCL/β2GPI) antibodies are representative antiphospholipid antibodies(aPLs) that target the complex of cardiolipin (or anionic molecules) and β2GPI. However, aCL is often regarded…Abstract Number: 2005 • 2015 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients
Background/Purpose: Epigenetic anomalies are emerging as striking pathogenic features of autoimmune disorders. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in regulatory networks that…Abstract Number: 2006 • 2015 ACR/ARHP Annual Meeting
Effect Size of the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017 in Rodent Models of Osteoarthritis
Background/Purpose : There is huge interest in the family of “A Disintegrin And Metalloproteinase with ThromboSpondin motifs” (ADAMTS) proteinases, especially aggrecanase-2 (ADAMTS-5), as therapeutic targets…Abstract Number: 2007 • 2015 ACR/ARHP Annual Meeting
Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis
Background/Purpose: Wnt has a key role in the formation of bone, cartilage and synovium. Increased Wnt signaling may contribute to initiation and progression of osteoarthritis…Abstract Number: 2008 • 2015 ACR/ARHP Annual Meeting
WISP1 Aggravates Osteoarthritis By Modulation of TGF-β Signaling and Positive Regulation of Canonical Wnt Signaling
Background/Purpose: Many osteoarthritis (OA) patients show synovial activation, which is suggested to be involved in joint destruction. Previously, we found synovial overexpression of Wnt ligands in experimental…Abstract Number: 2009 • 2015 ACR/ARHP Annual Meeting
CC-Chemokine Receptor 7 (CCR7) Deficiency Reduces Early Structural and Functional Features of Disease in a Murine Model of Osteoarthritis
Background/Purpose: Synovial expression of CCR7 has been associated with inflammation and severity of symptoms in patients with meniscal tears and early osteoarthritis (OA). This receptor…
ACR Meeting Abstracts